RT Journal Article
T1 Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis
A1 Marcianes, Patricia
A1 Negro Álvarez, María Sofía Elisa
A1 Barcia Hernández, Emilia María
A1 Montejo, Consuelo
A1 Fernández Carballido, Ana María
AB Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and represents one of the leading causes of mortality worldwide due to multidrug resistant TB (MDR-TB). In our work, a new formulation of biodegradable PLGA microparticles was developed for pulmonary administration of gatifloxacin, using a surface modifier agent to actively target alveolar macrophages thereby allowing to gain access of the drug to Mycobacterium tuberculosis. For this, rapid uptake of the particles by macrophages is beneficial. This process was evaluated with fluorescein-loaded microparticles using PLGA 502 or PLGA 502H as polymers and labrafil as surface modifier. Cell phagocytosis was studied in raw 264.7 mouse macrophage cell line after 3, 5, 24, and 48 h incubation with the microparticles. Labrafil enhanced the uptake rate of PLGA 502H microparticles by macrophages which was directly related to the modification of the polymer matrix. Gatifloxacin-loaded PLGA microparticles using PLGA 502 or PLGA 502H and labrafil were prepared. From our results, only microparticles prepared with PLGA 502H and labrafil exhibited high encapsulation efficiency (89.6 ± 0.2%), rapid phagocytosis by macrophages (3 h), and remained inside the cells for at least 48 h, thereby resulting in a suitable carrier to potentially treat MDR-TB.
PB Springer
SN 1530-9932
YR 2019
FD 2019
LK https://hdl.handle.net/20.500.14352/92449
UL https://hdl.handle.net/20.500.14352/92449
LA eng
NO Marcianes, P., Negro, S., Barcia, E. et al. Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis. AAPS PharmSciTech 21, 15 (2020). https://doi.org/10.1208/s12249-019-1552-3
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 14 dic 2025